Aphton announces tests with Gonadimmune result in inhibition of breast cancer growth and extended survival time equal to Tamoxifen.WOODLAND, Calif.--(BUSINESS WIRE)--Dec. 15, 1994--Aphton (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :APHT APHT Advance Physical Test ) announced that it has successfully concluded experiments designed to test the efficacy of Gonadimmune, its product for treating women with breast cancer and men with prostrate cancer. This immunogen elicits antibodies that neutralize and remove from circulation the patient's hormone called Gonadotrophin Gonadotrophin Hormones that stimulate the ovary and testicles. Mentioned in: Klinefelter Syndrome gonadotrophin (gōnad´ōtrōf´in), n See gonadotropin. Releasing Hormone (GnRH). This hormone in turn regulates the production of the steroid hormones testosterone, estrogen and progesterone; neutralizing GnRH results in blocking their production. These hormones are known to promote the growth of prostrate cancer (testosterone) and breast and endometrial cancers (estrogen). In animals carrying a human-derived breast cancer the neutralization neutralization, chemical reaction, according to the Arrhenius theory of acids and bases, in which a water solution of acid is mixed with a water solution of base to form a salt and water; this reaction is complete only if the resulting solution has neither acidic nor of GnRH with Gonadimmune-induced antibodies resulted in (a) inhibition of tumor growth and (b) extended survival time equal to tamoxifen tamoxifen (təmŏk`sĭfĕn'), synthetic hormone used in the treatment of breast cancer. Introduced in 1978, tamoxifen is used to prevent recurrences of cancer in women who have already undergone surgery to remove their tumors. , against which Gonadimmune was compared. Tamoxifen is currently the only anti-estrogen therapy available for treatment of breast cancer. However, it has recently been reported that tamoxifen increases the incidence of endometrial cancer in women who had been treated with tamoxifen for their breast cancer. It is anticipated that because of its different mode of action, Gonadimmune will be free of such complications. Immunization with Gonadimmune is expected to provide long-term protection measured in months, whereas tamoxifen requires daily doses. Aphton plans to apply for regulatory agency approval to initiate clinical trials with Gonadimmune for women with breast cancer in 1995. Aphton is now in the dose-ranging phase of a Phase I/II clinical trial in the UK with its lead product, Gastrimmune, for patients with colorectal cancer. Aphton also plans to start pivotal trials with Gastrimmune for gastroesophageal reflux disease gastroesophageal reflux disease (GERD) Disorder characterized by frequent passage of gastric contents from the stomach back into the esophagus. Symptoms of GERD may include heartburn, coughing, frequent clearing of the throat, and difficulty in swallowing. (GERD GERD gastroesophageal reflux disease. GERD abbr. gastroesophageal reflux disease GERD ), upon completion of the current Phase I/II clinical trial with Gastrimmune in 1995. Aphton is a biopharmaceutical company developing products for neutralizing hormones that participate in gastrointestinal and reproductive system malignant and non-malignant diseases. CONTACT: Aphton Corp.
Jeannette Whitmore, 305/374-6717
Cameron Associates Inc.
Melissa Wilmouth, 212/644-9560
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion